LAB vs RTX · rev $174.4M vs P/E 36, rev $88.60B
Standard Biotools Inc (LAB) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
LAB currently screens at market cap $317.1M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the LAB and RTX stock pages for the full models.
Not investment advice.